Next Phase Newsletter

The firm is the corporate venture arm of a diversified business based in Tokyo focused on three primary sectors: Materials, Homes and Healthcare. The team is based in offices outside Boston, MA and Menlo Park, CA. The fund has an evergreen structure looking to allocate between $1-$3 million per deal initially and up to $5 million over the life of the investment. They are seeking to invest in approximately 2-4 companies over the next 12 months and are open to investing in companies across the globe.

Sectors of interest include: pharmaceuticals, medical device and digital health. Therapeutic and product areas of interest include: Pain, critical care, musculoskeletal disease, kidney disease, DDS, patient monitoring technologies, bioprocessing technologies, digital therapeutics. The firm is open to all stages of investment, with a general preference toward companies with at least some early clinical data.

The firm invests in private companies and is willing to work with all types of management teams including incomplete teams. The firm generally requests at least an observer seat following investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.

The PE firm was founded in 1996 and has offices in California, China, Hong Kong and Taiwan. The firm is currently making investment from its USD 1.4B fund into promising private healthcare companies and from its $635M Opportunity Fund into promising public healthcare companies, invest in promising early-stage healthcare companies from its Innovation Fund. The firm invests exclusively in the healthcare sector; the firm invests primarily in the USA and Greater China but will also invest in other regions such as Europe and ASEAN countries. Within China, the firm makes growth investments in companies but also find some companies with interesting and innovative product in recent years there; in the USA and other regions, the firm makes both venture and growth-equity stage investments in both pre-revenue and revenue-stage companies. The firm’s allocations are highly varied. From the main fund, investments typically range from $20-50m, though larger investments are of interest as well; the firm’s Innovation Fund makes investments of typically $5-20 million. The firm is open to syndication. The firm is also particularly interested in working with companies that are open to or actively interested in seeking partnerships or opportunities in China.

The firm invests in therapeutics, medical devices, diagnostics, healthcare services, and clinically-oriented healthcare IT, and will consider investing in any indication area or technology subsector; however, orphan indications, dermatology/aesthetics, oncology, gene therapy, cell therapy, are of particular interest in the biopharma space; general surgery, neurovascular, cardiovascular, minimally invasive technologies, women’s health, respiratory care, novel diagnostics and orthopedics are of particular interest in the device space. Healthcare AI is an area we are interested and exploring. The Innovation Fund focuses on early-stage opportunities in biotech; from the main fund, the firm in most cases makes investments in products that have obtained market approval or are very close to commercialization, but earlier investments may be considered for highly innovative products or products that can demonstrate strong efficacy signals at an earlier stage (such as anti-infectives). For

devices and diagnostics, the firm only invests in commercial-stage companies. Generally, the firm does not invest in imaging.

The firm is flexible regarding management teams and works with both serial entrepreneurs and entrepreneurs who lack industry experience. In addition to investing in private companies, The firm is able to invest in public companies by means of PIPEs or public market placements. The firm is interested in investing in companies with products that can demonstrate cost-effectiveness.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.

The firm is a venture capital firm founded in 2021 and located in Basel, Switzerland. The firm is currently investing out of their first fund and looks to invest in early-stage life science companies in the therapeutics space. The firm focuses on Seed investments in the form of equity. Typical allocation is up to $5M for the first ticket. The firm invests in European companies.

The firm is interested in therapeutics, with a focus on oncology, immunology, rare diseases, fibrotic diseases and CNS. The firm will invest in pre-clinical therapeutic companies.

The firm has no specific company or management team requirements and is willing to work with all early-stage companies globally, with promising technologies. The firm prefers to lead investments and seeks board seat representation.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.

A multi-family office with offices in Asia is joined by a group of families with minimum personal or family asset of 30 million USD. Typical Allocations Size of the firm is around $1.5M. The firm does not have a strict limit to the number of new investments.

The firm is open to investing in general Bio-medical industries, including medical devices, healthcare IT and therapeutics. The firm has a preference for reproductive medicine and eye-related topics. Any kind of technology, device or service are welcomed under these 2 topics. Besides the topics above, the firm is currently looking for pre-clinical and phase I opportunities in therapeutic companies as well as medical devices and healthcare IT companies that are in development. Apart from the bio-medical industry, the firm also focuses on investing in E-Vehicle related startups.

The firm is looking for companies with Asia Angle, preferably Asia-based or those plan to do R&D in Asia. The firm is typically a co-investor.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A publicly traded pharmaceutical company is interested in licensing and M&A opportunities in its core therapeutic areas of urology, cardiovascular, gastrointestinal and metabolic diseases, and also in all rare disease/orphan drug assets. The firm will consider partnerships worldwide.  Particularly in the rare disease space, the firm prefers to invest in global rights.

The firm is interested in early stage therapeutic partnerships in rare diseases, including in preclinical assets provided that there is strong preclinical proof of concept data for the asset (such as strong efficacy data from an animal model that are relevant and reflective of the human condition). The firm generally does not invest in rare oncology assets but is otherwise open to a wide range of rare disease opportunities. In other core areas (urology, cardiovascular, gastrointestinal, and  central nervous system) the firm prefers to partner with companies that have obtained solid human proof of concept data. The firm can be a hands-on development and manufacturing partner in small molecule therapeutics, but not in biologics or cell therapies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A corporate venture arm of a diversified business based in Japan is focused on three primary sectors, one of them being healthcare. The team has offices throughout the USA.  The fund has an evergreen structure looking to allocate between $1-$3 million per deal initially and up to $5 million over the life of the investment. They are seeking to invest in approximately 2-4 companies over the next 12 months and are open to investing in companies across the globe.

Sectors of interest include: pharmaceuticals, medical device and digital health. Therapeutic and product areas of interest include: Pain, critical care, musculoskeletal disease, kidney disease, DDS, patient monitoring technologies, bioprocessing technologies, digital therapeutics. The firm is open to all stages of investment, with a general preference toward companies with at least some early clinical data.

The firm invests in private companies and is willing to work with all types of management teams including incomplete teams. The firm generally requests at least an observer seat following investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture builder headquartered in Western Europe seeks to build new ventures from scratch, generating innovation in novel science and technology from the earliest stages of development. Currently, the firm is focused on 4 main pillars: energy, agriculture, curative therapeutics, and computation. The firm invests pre-seed/seed capital into the companies they build. The firm will consider global opportunities.

Within life sciences, the firm is indication agnostic and has worked in areas including cystic fibrosis, oncology, neurodegeneration and microbiome. The firm has a strong interest in cell & gene therapy and synthetic biology, but is open to considering all other modalities – the firm has also launched companies that work on a more traditional approach.

In terms of stage of development, the firm invests in the companies it builds at formation stage and is open to working together with other organizations to undertake company creation and support proof-of-concept data generation. The firm generally does not currently build, or invest in, medical devices, diagnostics, or digital health companies.

As a venture builder, the firm does not have strict requirements or expectations on company operations or management team. The firm has generally built companies in Western Europe. That said, the firm has worked with scientists all across the globe to build its companies, and their portfolio also includes companies in other geographies such as the USA.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.